Anti–Methicillin-Resistant Staphylococcus aureus Nanoantibiotics

Labruère, Raphaël; Sona, Amanda J.; Turos, Edward

doi:10.3389/fphar.2019.01121

Cited by 48 publications

(39 citation statements)

References 213 publications

(236 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While EPO enhanced the clearance of the Gram-negative pathogen E. coli, its effects on Gram-positive bacteria are unknown. S. aureus is a Gram-positive bacterial pathogen that is responsible for significant morbidity and mortality worldwide and it is the leading cause of skin infection (32)(33)(34). Therefore, we investigated the effects of EPO on S. aureus infection.…”

Section: Epo Promotes Bacterial Phagocytosis and Enhances Vancomycin Actions In S Aureus-initiated Infectionsmentioning

confidence: 99%

Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in E. coli- and S. aureus-Initiated Infections

Liang

Guan

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Endogenous mechanisms underlying bacterial infection resolution are essential for the development of novel therapies for the treatment of inflammation caused by infection without unwanted side effects. Herein, we found that erythropoietin (EPO) promoted the resolution and enhanced antibiotic actions in Escherichia coli (E. coli)- and Staphylococcus aureus (S. aureus)-initiated infections. Levels of peritoneal EPO and macrophage erythropoietin receptor (EPOR) were elevated in self-limited E. coli-initiated peritonitis. Myeloid-specific EPOR-deficient mice exhibited an impaired inflammatory resolution and exogenous EPO enhanced this resolution in self-limited infections. Mechanistically, EPO increased macrophage clearance of bacteria via peroxisome proliferator-activated receptor γ (PPARγ)-induced CD36. Moreover, EPO ameliorated inflammation and increased the actions of ciprofloxacin and vancomycin in resolution-delayed E. coli- and S. aureus-initiated infections. Collectively, macrophage EPO signaling is temporally induced during infections. EPO is anti-phlogistic, increases engulfment, promotes infection resolution, and lowers antibiotic requirements.

show abstract

Section: Epo Promotes Bacterial Phagocytosis and Enhances Vancomycin Actions In S Aureus-initiated Infectionsmentioning

confidence: 99%

Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in E. coli- and S. aureus-Initiated Infections

Liang

Guan

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In 1960, the methicillin-resistant S. aureus (MRSA) strains were detected ( Chambers and Deleo, 2009 ), and those are still a current cause of soft tissue infections. New effective antibiotic therapies are a current demand ( Yang et al, 2018 ; Labruère et al, 2019 ). The application of bacteriophages as a therapy to treat S. aureus infections ( Kaźmierczak et al, 2014 ) is a promising alternative.…”

Section: Introductionmentioning

confidence: 99%

Identification and Characterization of the CRISPR/Cas System in Staphylococcus aureus Strains From Diverse Sources

et al. 2021

View full text Add to dashboard Cite

The CRISPR-Cas [clustered regularly interspaced short palindromic repeats and the CRISPR-associated genes (Cas)] system provides defense mechanisms in bacteria and archaea vs. mobile genetic elements (MGEs), such as plasmids and bacteriophages, which can either be harmful or add sequences that can provide virulence or antibiotic resistance. Staphylococcus aureus is a Gram-positive bacterium that could be the etiological agent of important soft tissue infections that can lead to bacteremia and sepsis. The role of the CRISPR-Cas system in S. aureus is not completely understood since there is a lack of knowledge about it. We analyzed 716 genomes and 1 genomic island from GENOMES-NCBI and ENA-EMBL searching for the CRISPR-Cas systems and their spacer sequences (SSs). Our bioinformatic analysis shows that only 0.83% (6/716) of the analyzed genomes harbored the CRISPR-Cas system, all of them were subtype III-A, which is characterized by the presence of the cas10/csm1 gene. Analysis of SSs showed that 91% (40/44) had no match to annotated MGEs and 9% of SSs corresponded to plasmids and bacteriophages, indicating that those phages had infected those S. aureus strains. Some of those phages have been proposed as an alternative therapy in biofilm-forming or infection with S. aureus strains, but these findings indicate that such antibiotic phage strategy would be ineffective. More research about the CRISPR/Cas system is necessary for a bigger number of S. aureus strains from different sources, so additional features can be studied.

show abstract

“…Various types of NPs loaded with antimicrobial agents are used as alternative treatments of MRSA infections, and have demonstrated therapeutic advantages compared to conventional formulations [ 36 ]. Furthermore, NPs that can deliver antibiotics to intracellular pathogens (such as MRSA) can treat persistent and/or re-occurring infections [ 37 ]. Several examples of various NP formulations used against MRSA are mentioned below.…”

Section: Nanosystems As Antimicrobial Treatments Of Infectionsmentioning

confidence: 99%

Nanobiosystems for Antimicrobial Drug-Resistant Infections

et al. 2021

View full text Add to dashboard Cite

The worldwide increased bacterial resistance toward antimicrobial therapeutics has led investigators to search for new therapeutic options. Some of the options currently exploited to treat drug-resistant infections include drug-associated nanosystems. Additionally, the use of bacteriophages alone or in combination with drugs has been recently revisited; some studies utilizing nanosystems for bacteriophage delivery have been already reported. In this review article, we focus on nine pathogens that are the leading antimicrobial drug-resistant organisms, causing difficult-to-treat infections. For each organism, the bacteriophages and nanosystems developed or used in the last 20 years as potential treatments of pathogen-related infections are discussed. Summarizing conclusions and future perspectives related with the potential of such nano-antimicrobials for the treatment of persistent infections are finally highlighted.

show abstract

Anti–Methicillin-Resistant Staphylococcus aureus Nanoantibiotics

Cited by 48 publications

References 213 publications

Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in E. coli- and S. aureus-Initiated Infections

Erythropoietin Promotes Infection Resolution and Lowers Antibiotic Requirements in E. coli- and S. aureus-Initiated Infections

Identification and Characterization of the CRISPR/Cas System in Staphylococcus aureus Strains From Diverse Sources

Nanobiosystems for Antimicrobial Drug-Resistant Infections

Contact Info

Product

Resources

About